106 related articles for article (PubMed ID: 25739418)
1. Response.
Nagayama A; Hayashida T; Jinno H; Takahashi M; Kitagawa Y
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25739418
[No Abstract] [Full Text] [Related]
2. RE: Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
Qi X; Ji LJ; Zhang X; Ma Y; Ma W
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25739417
[No Abstract] [Full Text] [Related]
3. Making sense of dual HER2-targeting in early breast cancer?
Carey LA; Barry W
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224563
[No Abstract] [Full Text] [Related]
4. Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer.
Brede-Hekimian K
Lancet; 2012 Jun; 379(9833):2237; author reply 2238. PubMed ID: 22704161
[No Abstract] [Full Text] [Related]
5. Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer.
Fujita T
Lancet; 2012 Jun; 379(9833):2237; author reply 2238. PubMed ID: 22704160
[No Abstract] [Full Text] [Related]
6. Dual HER2 targeting for early breast cancer.
Johnston SR
Lancet Oncol; 2013 Nov; 14(12):1145-6. PubMed ID: 24095298
[No Abstract] [Full Text] [Related]
7. Dual inhibition of HER2 in breast cancer treatment.
Gnant M; Steger GG
Lancet; 2012 Feb; 379(9816):596-8. PubMed ID: 22257672
[No Abstract] [Full Text] [Related]
8. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
Nagayama A; Hayashida T; Jinno H; Takahashi M; Seki T; Matsumoto A; Murata T; Ashrafian H; Athanasiou T; Okabayashi K; Kitagawa Y
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224562
[TBL] [Abstract][Full Text] [Related]
9. Targeted treatments for breast cancer: a step forward.
Bachelot T; Tredan O
Lancet Oncol; 2013 May; 14(6):438-9. PubMed ID: 23602602
[No Abstract] [Full Text] [Related]
10. Hints of future progress for HER-2 breast cancer.
Twombly R
J Natl Cancer Inst; 2011 Apr; 103(7):535-7. PubMed ID: 21436059
[No Abstract] [Full Text] [Related]
11. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?
Esteva FJ; Hortobagyi GN
J Natl Cancer Inst; 2008 Apr; 100(8):521-3. PubMed ID: 18398093
[No Abstract] [Full Text] [Related]
12. [HER2-positive breast cancer: standard and double targeted therapy].
Semiglazov VF; Bozhok AA; Semiglazova TIu; Vasil'ev AG; Manikhas AG; Semiglazov VV; Bessonov AA; Nikolaev KS
Vopr Onkol; 2013; 59(3):341-6. PubMed ID: 23909035
[TBL] [Abstract][Full Text] [Related]
13. Better treatments needed for breast cancer brain metastases.
Lin NU
Lancet Oncol; 2015 Dec; 16(16):1583-4. PubMed ID: 26596673
[No Abstract] [Full Text] [Related]
14. Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy.
Prat A; Baselga J
J Clin Oncol; 2013 May; 31(14):1703-6. PubMed ID: 23569319
[No Abstract] [Full Text] [Related]
15. Pertuzumab (Perjeta) for preoperative use in HER2-positive breast cancer.
Med Lett Drugs Ther; 2013 Dec; 55(1431):98-9. PubMed ID: 24322664
[No Abstract] [Full Text] [Related]
16. The Dual Role of Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Two Sides of the Same Coin?
Loibl S
JAMA Oncol; 2015 Jul; 1(4):455-6. PubMed ID: 26181253
[No Abstract] [Full Text] [Related]
17. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab and Cardiac Outcomes in Breast Cancer: A Story We Know by Heart?
Milano G; Chamorey E; Ferrero JM
JAMA Oncol; 2016 Jan; 2(1):21-2. PubMed ID: 26540493
[No Abstract] [Full Text] [Related]
19. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
20. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
